The efficacy of capmatinib was evaluated in a phase 2 clinical study across several cohorts of patients with MET-dysregulated advanced NSCLC (MET exon 14 skipping mutation or MET amplification), with administration of the 400 mg oral tablet twice per day. This evidence concerns the gene MET and non-small cell lung carcinoma.